ERBB2 and cancer: Despite the establishment of first-line combination therapies containing a fluoropyrimidine and a platinum agent (supplemented with the anti-HER2 antibody trastuzumab for patients with cancer over-expressing HER2), and second-line paclitaxel with or without ramucirumab, as standard treatments for advanced unresectable or recurrent gastric cancer (AGC), median survival is only 12–15 months.